These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 152600)

  • 1. Inhibitors of GABA metabolism: implications for Huntington's disease.
    Schwarcz R; Bennett JP; Coyle JT
    Ann Neurol; 1977 Oct; 2(4):299-303. PubMed ID: 152600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An animal model for Huntington's disease.
    Coyle JT
    Biol Psychiatry; 1979 Apr; 14(2):251-76. PubMed ID: 38864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo action of enzyme-activated irreversible inhibitors of glutamic acid decarboxylase and gamma-aminobutyric acid transaminase in retina vs. brain.
    Cubells JF; Blanchard JS; Smith DM; Makman MH
    J Pharmacol Exp Ther; 1986 Aug; 238(2):508-14. PubMed ID: 3735130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular effects of GABA, GABA-aminotransferase inhibitors and valproic acid following systemic administration in rats, cats and dogs: pharmacological approach to localize the site of action.
    Löscher W
    Arch Int Pharmacodyn Ther; 1982 May; 257(1):32-58. PubMed ID: 6810779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of gamma-vinyl GABA alone or associated with diazepam on a conflict test in the rat.
    Huot S; Robin M; Palfreyman MG
    Adv Biochem Psychopharmacol; 1981; 29():45-52. PubMed ID: 7257938
    [No Abstract]   [Full Text] [Related]  

  • 6. Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease.
    Lastres-Becker I; Hansen HH; Berrendero F; De Miguel R; Pérez-Rosado A; Manzanares J; Ramos JA; Fernández-Ruiz J
    Synapse; 2002 Apr; 44(1):23-35. PubMed ID: 11842443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proceedings: Comparison of circling behaviour following unilateral inhibition of GABA-transaminase or discrete electroyltic lesioning in the rat substantia nigra.
    Dray A; Fowler LJ; Oakley NR; Simmonds MA; Tanner T
    Br J Pharmacol; 1975 Oct; 55(2):288P. PubMed ID: 1238134
    [No Abstract]   [Full Text] [Related]  

  • 8. Changes in primary afferent depolarization after administration of gamma-acetylenic gamma aminobutyric acid (GAG), a gamma-aminobutyric acid (GABA) transaminase inhibitor.
    Larson AA; Anderson EG
    J Pharmacol Exp Ther; 1979 Nov; 211(2):326-30. PubMed ID: 501564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiseizure activity of gamma-acetylenic gamma-aminobutyric acid: a catalytic irreversible inhibitor of gamma-aminobutyric acid transaminase.
    Schechter PJ; Tranier Y; Jung MJ; Sjoerdsma A
    J Pharmacol Exp Ther; 1977 Jun; 201(3):606-12. PubMed ID: 864598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interconnection of GABA-ergic neurons in rat extrapyramidal tract: analysis using intracerebral microinjection of kainic acid.
    Kurihara E; Kuriyama K; Yoneda Y
    Exp Neurol; 1980 Apr; 68(1):12-26. PubMed ID: 7363980
    [No Abstract]   [Full Text] [Related]  

  • 11. [On the mechanism of action of valproid acid].
    Löscher W; Frey HH
    Arzneimittelforschung; 1977; 27(5):1081-2. PubMed ID: 328017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronology of neurochemical alterations induced by GABA agonist administration.
    Enna SJ; Ferkany JW; Butler IJ
    Adv Biochem Psychopharmacol; 1981; 26():181-9. PubMed ID: 7457233
    [No Abstract]   [Full Text] [Related]  

  • 13. Metabolic inhibitors and subcellular distribution of GABA.
    Sarhan S; Seiler N
    J Neurosci Res; 1979; 4(5-6):399-421. PubMed ID: 392122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Luteinizing hormone release induced by noradrenaline after administration of drugs that increase hypothalamic GABA levels.
    Donoso AO
    Acta Physiol Pharmacol Latinoam; 1988; 38(1):11-8. PubMed ID: 3201990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of gamma-aminobutyric acid (GABA)-elevating agents on the neuroleptic-induced activation of striatal tyrosine-hydroxylase: evidence that di-n-propylacetate augments GABAergic neurotransmission.
    Casu M; Gale K
    J Pharmacol Exp Ther; 1981 Apr; 217(1):177-80. PubMed ID: 6110774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of 4-amino hex-5-ynoic acid (gamma-acetylenic GABA, gammma-ethynyl GABA) a catalytic inhibitor of GABA transaminase, on brain GABA metabolism in vivo.
    Jung MJ; Lippert B; Metcalf BW; Schechter PJ; Böhlen P; Sjoerdsma A
    J Neurochem; 1977 Apr; 28(4):717-23. PubMed ID: 894280
    [No Abstract]   [Full Text] [Related]  

  • 17. The cortical lesion of Huntington's disease: further neurochemical characterization, and reproduction of some of the histological and neurochemical features by N-methyl-D-aspartate lesions of rat cortex.
    Storey E; Kowall NW; Finn SF; Mazurek MF; Beal MF
    Ann Neurol; 1992 Oct; 32(4):526-34. PubMed ID: 1280937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The IGF-I amino-terminal tripeptide glycine-proline-glutamate (GPE) is neuroprotective to striatum in the quinolinic acid lesion animal model of Huntington's disease.
    Alexi T; Hughes PE; van Roon-Mom WM; Faull RL; Williams CE; Clark RG; Gluckman PD
    Exp Neurol; 1999 Sep; 159(1):84-97. PubMed ID: 10486177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced GABA transaminase activity in the Huntington's disease putamen.
    Carter CJ
    Neurosci Lett; 1984 Aug; 48(3):339-42. PubMed ID: 6237280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracerebral injection of gamma vinyl GABA: method for measuring rates of GABA synthesis in specific brain regions in vivo.
    Casu M; Gale K
    Life Sci; 1981 Aug; 29(7):681-8. PubMed ID: 7278507
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.